Actively Recruiting
A Retrospective Real-World Study Based on RATIONALE-307
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-03-27
109
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
CONDITIONS
Official Title
A Retrospective Real-World Study Based on RATIONALE-307
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
You will not qualify if you...
- Patients who had a documented death before study completion in the RATIONALE-307 trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Actively Recruiting
Research Team
Z
Zhijie Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here